Trials / Completed
CompletedNCT04832399
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Natalizumab | As described in the treatment arm. |
Timeline
- Start date
- 2013-11-12
- Primary completion
- 2023-10-02
- Completion
- 2023-10-02
- First posted
- 2021-04-05
- Last updated
- 2024-02-05
Locations
18 sites across 1 country: Portugal
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04832399. Inclusion in this directory is not an endorsement.